Results 301 to 310 of about 1,719,335 (360)
Path analysis of predictors of frailty in hospitalised patients with chronic obstructive pulmonary disease. [PDF]
Sci RepJiang H, Pan L, Yang Y, Hong Y.
europepmc +1 more source
Identification and validation of USP15 and CUL2 as ubiquitination related biomarker in chronic obstructive pulmonary disease. [PDF]
HereditasSun S, Zhang Z, Zhao H.
europepmc +1 more source
Proteomic biomarkers of emphysema-predominant and non-emphysema-predominant chronic obstructive pulmonary disease. [PDF]
EBioMedicineZhang YH +11 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Infectious Disease Clinics of North America, 2022
Pneumonia is a lower respiratory tract infection caused by the inability to clear pathogens from the lower airway and alveoli. Cytokines and local inflammatory markers are released, causing further damage to the lungs through the accumulation of white blood cells and fluid congestion, leading to pus in the parenchyma. The Infectious Diseases Society of
Rachel Rafeq, Lauren A. Igneri
openaire +3 more sources
Pneumonia is a lower respiratory tract infection caused by the inability to clear pathogens from the lower airway and alveoli. Cytokines and local inflammatory markers are released, causing further damage to the lungs through the accumulation of white blood cells and fluid congestion, leading to pus in the parenchyma. The Infectious Diseases Society of
Rachel Rafeq, Lauren A. Igneri
openaire +3 more sources
Medical Clinics of North America, 1996
This article has presented the reader with an overview of the pulmonary disorders that develop during the course of HIV disease with special emphasis on the more commonly encountered entities. This information is intended to prepare the clinician to recognize the hallmark characteristics of the various diseases as well as atypical features. Despite the
P A, Walker, D A, White
openaire +2 more sources
This article has presented the reader with an overview of the pulmonary disorders that develop during the course of HIV disease with special emphasis on the more commonly encountered entities. This information is intended to prepare the clinician to recognize the hallmark characteristics of the various diseases as well as atypical features. Despite the
P A, Walker, D A, White
openaire +2 more sources
Comprehensive Physiology, 2011
AbstractDiseases of the pulmonary vasculature are a cause of increased pulmonary vascular resistance (PVR) in pulmonary embolism, chronic thromboembolic pulmonary hypertension (CTEPH), and pulmonary arterial hypertension or decreased PVR in pulmonary arteriovenous malformations on hereditary hemorrhagic telangiectasia, portal hypertension, or ...
Melot, Christian, Naeije, Robert
openaire +3 more sources
AbstractDiseases of the pulmonary vasculature are a cause of increased pulmonary vascular resistance (PVR) in pulmonary embolism, chronic thromboembolic pulmonary hypertension (CTEPH), and pulmonary arterial hypertension or decreased PVR in pulmonary arteriovenous malformations on hereditary hemorrhagic telangiectasia, portal hypertension, or ...
Melot, Christian, Naeije, Robert
openaire +3 more sources
Nursing Management, 2012
NHS Improvement has added four publications to its chronic obstructive pulmonary disease (COPD) section.
openaire +2 more sources
NHS Improvement has added four publications to its chronic obstructive pulmonary disease (COPD) section.
openaire +2 more sources
The American Journal of Cardiology, 2015
In recent years, numerous studies have focused on the use of soluble ST2 (sST2) as a clinical biomarker for cardiovascular disease. However, much preclinical data points to involvement of the ST2 pathway in inflammation, and specifically in pulmonary inflammation. This report summarizes the current body of clinical data suggesting the potential role of
James L. Januzzi +2 more
openaire +3 more sources
In recent years, numerous studies have focused on the use of soluble ST2 (sST2) as a clinical biomarker for cardiovascular disease. However, much preclinical data points to involvement of the ST2 pathway in inflammation, and specifically in pulmonary inflammation. This report summarizes the current body of clinical data suggesting the potential role of
James L. Januzzi +2 more
openaire +3 more sources